Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 5/20 | 0.69 |
| ▸ | GSK3B | P49841 | 3/20 | 0.69 |
| ▸ | KIT | P10721 | 2/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | JAK3 | P52333 | 6/20 | 0.63 |
| ▸ | BTK | Q06187 | 4/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211286 | 0.85 | BTK (0.79) | JAK3BTKDOT1L | |
| SCHEMBL2048915 | 0.82 | AKT2 (0.70) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL2022699 | 0.82 | AKT2 (0.78) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL1003408 | 0.82 | AKT2 (1.00) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL30673936 | 0.82 | AKT2 (1.00) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL2019251 | 0.82 | AKT2 (0.83) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL2019457 | 0.81 | LCK (1.00) | AKT2GSK3BKITLCKJAK3 | |
| Hydrochloric Acid SCHEMBL29036033 | 0.81 | AKT2 (0.97) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL1789204 | 0.81 | RPS6KB1 (0.72) | AKT2GSK3BKITLCKJAK3 | |
| SCHEMBL3920712 | 0.80 | AKT2 (1.00) | AKT2GSK3BKITLCKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
| US-7569569-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| EP-1087971-B1 | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS | PFIZER PROD INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| CN-1125070-C | Pyrrolo [2,3-d] pyrmidine compounds | PFIZER PROD INC (US) | 2003-10-22 | — | — | CN | disclosed |
| US-6635762-B1 | Protein tyrosine kinase or Janus Kinase 3 inhibitors; immunosuppressants | PFIZER INC. | 2003-10-21 | — | — | US | disclosed |
| CN-1305479-A | Pyrrolo [2,3-d] pyrmidine compounds | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | AKT2 1555/4885GSK3B 1050/4885KIT 449/4885 |
| US-20040058922-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | AKT2 731/4885GSK3B 666/4885KIT 1752/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | AKT2 1555/4885GSK3B 1050/4885KIT 449/4885 |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | AKT2 7/4885GSK3B 42/4885KIT 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.